Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer’s dementia in very old age: A retrospective observational study

Objective: To provide pilot data for the safety and efficacy of EGb 761 in the oldest-old patients (aged 80 or older). Materials and methods: In a retrospective analysis, we compared treatment outcomes with EGb 761 or donepezil over 12 months in 189 patients aged 80 years or older suffering from Alz...

Descripción completa

Detalles Bibliográficos
Autores principales: Rapp, Michael, Burkart, Martin, Kohlmann, Thomas, Bohlken, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822177/
https://www.ncbi.nlm.nih.gov/pubmed/29319499
http://dx.doi.org/10.5414/CP203103
Descripción
Sumario:Objective: To provide pilot data for the safety and efficacy of EGb 761 in the oldest-old patients (aged 80 or older). Materials and methods: In a retrospective analysis, we compared treatment outcomes with EGb 761 or donepezil over 12 months in 189 patients aged 80 years or older suffering from Alzheimer’s disease (AD). Results: Over 12 months, there was no significant difference in cognitive decline, measured with the mini-mental state examination (MMSE) score, between donepezil and EGb 761 (p = 0.31). We found more adverse events in the donepezil group. Conclusion: Results suggest similar effects on cognitive symptoms from the use of EGb 761 in the treatment of dementia in AD together with favorable safety compared to donepezil.

Ejemplares similares